Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPE-791 in Idiopathic Pulmonary Fibrosis
NCT07284459Phase 2Recruiting
- Sponsor
- Contineum Therapeutics
- Start
- Jan 2026
- Primary completion
- May 2028
- Countries
- 19
01
Overview
A Phase 2 trial of PIPE-791 in idiopathic pulmonary fibrosis (IPF), sponsored by Contineum Therapeutics. Started Jan 2026; status: recruiting.
02
Drugs
PIPE-791
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07284459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07284459.